Home » Stocks » CNSP

CNS Pharmaceuticals, Inc. (CNSP)

Stock Price: $1.98 USD -0.10 (-4.81%)
Updated Apr 19, 2021 3:41 PM EDT - Market open
Market Cap 51.61M
Revenue (ttm) n/a
Net Income (ttm) -9.46M
Shares Out 23.86M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $1.98
Previous Close $2.08
Change ($) -0.10
Change (%) -4.81%
Day's Open 2.10
Day's Range 1.90 - 2.24
Day's Volume 496,785
52-Week Range 1.59 - 4.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HOUSTON, March 15, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a...

1 month ago - PRNewsWire

CNS Pharmaceuticals Inc's (NASDAQ: CNSP) partner WPD Pharmaceuticals received a favorable opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland, for its planned upcoming Beru...

2 months ago - Benzinga

HOUSTON, Feb. 18, 2021 /PRNewswire/ -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD") and CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), biopharmaceutical companies specializing in ...

2 months ago - PRNewsWire

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

Other stocks mentioned: AMRS, CYRN, MREO, NGD, RARE, XELA
3 months ago - InvestorPlace

HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc . (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

3 months ago - GlobeNewsWire

HOUSTON, Dec. 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

4 months ago - PRNewsWire

HOUSTON, Dec. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

4 months ago - PRNewsWire

HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and me...

4 months ago - GlobeNewsWire

HOUSTON, Oct. 9, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

6 months ago - PRNewsWire

HOUSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel t...

6 months ago - GlobeNewsWire

HOUSTON, Sept. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

7 months ago - PRNewsWire

Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of n...

7 months ago - GlobeNewsWire

HOUSTON, Aug. 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

7 months ago - PRNewsWire

HOUSTON, Aug. 20, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc.

7 months ago - PRNewsWire

HOUSTON, July 22, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

8 months ago - PRNewsWire

HOUSTON, July 8, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

9 months ago - PRNewsWire

HOUSTON, May 28, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

10 months ago - PRNewsWire

HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

10 months ago - PRNewsWire

HOUSTON, May 27, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

10 months ago - PRNewsWire

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company.

Other stocks mentioned: MBRX
11 months ago - Market Watch

HOUSTON, May 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

11 months ago - PRNewsWire

Moleculin Biotech Inc. MBRX, -1.83% and CNS Pharmaceuticals Inc. CNSP, -3.83% said Monday they did not solicit or have any advance knowledge about claims made by third parties about drug candidate WP112...

Other stocks mentioned: MBRX
11 months ago - Market Watch

CNS Pharmaceuticals (NASDAQ: CNSP) shares are trading higher on Monday. The company announced that independent research from the University of Frankfurt showed that an active compound in WP1122 complete...

1 year ago - Benzinga

Nano-cap biotech CNS Pharmaceuticals Inc (NASDAQ: CNSP), which develops treatments for cancers of the brain and central nervous systems, said Monday that it has struck an agreement with Canada's WPD Pha...

1 year ago - Benzinga

CNS Pharmaceuticals, Inc. (CNSP) Management on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based i... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 2019
Stock Exchange
NASDAQ
Ticker Symbol
CNSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CNSP stock is "Buy." The 12-month stock price forecast is 8.33, which is an increase of 320.71% from the latest price.

Price Target
$8.33
(320.71% upside)
Analyst Consensus: Buy